

Market Announcement

23 June 2025

Microba Life Sciences Limited (ASX: MAP) – Suspension from Quotation

The securities of Microba Life Sciences Limited ('MAP') will be suspended from quotation immediately under Listing Rule 17.2 at the request of MAP, pending the release of an announcement by MAP.

Unless ASX decides otherwise, the securities will remain suspended until the earlier of:

- the end of the period stated in MAP's request for voluntary suspension; or
- the release of the announcement to the market.

MAP's request for voluntary suspension is attached below for the information of the market.

Issued by

ASX Compliance

Mr Inderprit Singh
Adviser Listings ASX Compliance (Sydney)
20 Bridge Street
SYDNEY, NSW 2000

By email: tradinghaltssydney@asx.com.au

Request for a voluntary suspension

Microba Life Sciences Ltd (ASX:MAP) (**Microba**), requests a voluntary suspension of all its quoted securities to apply from the commencement of trading on Monday, 23 June 2025.

The voluntary suspension is requested in relation to a proposed capital raise (**Capital Raise**).

In accordance with Listing Rule 17.2, Microba provides the following information in relation to this request:

1. Microba is seeking a voluntary suspension pending the announcement of its Capital Raise;
2. It is requested that the voluntary suspension be put in place until Microba is in a position to announce the Capital Raise, which it is expected to be no later than Tuesday, 24 June 2025;
3. Microba is not aware of any reason why the voluntary suspension should not be granted; and
4. Microba is not aware of any other information necessary to inform the market about the voluntary suspension.

Yours sincerely,



James Heath
Company Secretary

This announcement has been authorised for release by the Chair and Chief Executive Officer.

For further information, please contact:

Dr Luke Reid
Chief Executive Officer
luke.reid@microba.com

Investor / Media Relations
investor@microba.com
<https://ir.microba.com/welcome>

About Microba Life Sciences Limited

Microba Life Sciences is a company at the forefront of microbiome diagnostics & therapeutics and are on a mission to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. For more information visit www.microba.com



JOIN MICROBA'S INTERACTIVE INVESTOR HUB

For more Company information and to engage with management by asking questions about Microba's latest announcements and updates, visit ir.microba.com/welcome

Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621